Chilton Capital Management
BEAM icon

Chilton Capital Management’s Beam Therapeutics BEAM Stock Holding History

Chilton Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-125
Closed -$3.83K – 544
2023
Q1 		$3.83K Buy
+125
New +$4.93K ﹤0.01% 503

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chilton Capital Management's BEAM Position: Q2 2023 in Review

Chilton Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 125 shares — an estimated $3.83K sold.

Chilton Capital Management first reported a position in BEAM in Q1 2023 and held it in 1 quarter. The position peaked at $3.83K in Q1 2023. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Chilton Capital Management reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Chilton Capital Management sold 125 Beam Therapeutics shares in Q2 2023, an estimated $3.83K.
  • Chilton Capital Management first reported a position in Beam Therapeutics in Q1 2023 and held it in 1 quarter.
  • Chilton Capital Management's Beam Therapeutics position peaked at $3.83K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Chilton Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.